vs

Side-by-side financial comparison of Core Laboratories Inc. (CLB) and Liquidia Corp (LQDA). Click either name above to swap in a different company.

Core Laboratories Inc. is the larger business by last-quarter revenue ($121.8M vs $92.0M, roughly 1.3× Liquidia Corp). Liquidia Corp runs the higher net margin — 15.8% vs 4.2%, a 11.6% gap on every dollar of revenue. On growth, Liquidia Corp posted the faster year-over-year revenue change (3054.6% vs -1.4%). Liquidia Corp produced more free cash flow last quarter ($42.2M vs $517.0K).

Abbott Laboratories, commonly known as Abbott, is an American multinational medical devices and health care company with headquarters in Abbott Park, Illinois. The company produces pharmaceuticals for sale outside the United States, diagnostic products, nutritional products, and medical devices.

Liquidia Corp is a late-stage biopharmaceutical firm focused on developing and commercializing innovative inhaled therapies for respiratory and rare diseases. It uses its proprietary PRINT particle engineering tech to create optimized drug products, with core markets in North America covering pulmonary arterial hypertension and asthma indications.

CLB vs LQDA — Head-to-Head

Bigger by revenue
CLB
CLB
1.3× larger
CLB
$121.8M
$92.0M
LQDA
Growing faster (revenue YoY)
LQDA
LQDA
+3056.1% gap
LQDA
3054.6%
-1.4%
CLB
Higher net margin
LQDA
LQDA
11.6% more per $
LQDA
15.8%
4.2%
CLB
More free cash flow
LQDA
LQDA
$41.7M more FCF
LQDA
$42.2M
$517.0K
CLB

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
CLB
CLB
LQDA
LQDA
Revenue
$121.8M
$92.0M
Net Profit
$5.1M
$14.6M
Gross Margin
Operating Margin
1.5%
21.5%
Net Margin
4.2%
15.8%
Revenue YoY
-1.4%
3054.6%
Net Profit YoY
137.9%
EPS (diluted)
$0.11
$0.18

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CLB
CLB
LQDA
LQDA
Q1 26
$121.8M
Q4 25
$138.3M
$92.0M
Q3 25
$134.5M
$54.3M
Q2 25
$130.2M
Q1 25
$123.6M
Q4 24
$129.2M
Q3 24
$134.4M
Q2 24
$130.6M
Net Profit
CLB
CLB
LQDA
LQDA
Q1 26
$5.1M
Q4 25
$4.9M
$14.6M
Q3 25
$14.2M
$-3.5M
Q2 25
$10.6M
Q1 25
$-154.0K
Q4 24
$7.4M
Q3 24
$11.7M
Q2 24
$9.0M
Gross Margin
CLB
CLB
LQDA
LQDA
Q1 26
Q4 25
20.8%
Q3 25
22.0%
Q2 25
20.3%
Q1 25
19.5%
Q4 24
17.8%
Q3 24
20.5%
Q2 24
21.2%
Operating Margin
CLB
CLB
LQDA
LQDA
Q1 26
1.5%
Q4 25
11.5%
21.5%
Q3 25
15.6%
3.3%
Q2 25
11.7%
Q1 25
3.6%
Q4 24
11.0%
Q3 24
14.7%
Q2 24
12.3%
Net Margin
CLB
CLB
LQDA
LQDA
Q1 26
4.2%
Q4 25
3.6%
15.8%
Q3 25
10.6%
-6.5%
Q2 25
8.2%
Q1 25
-0.1%
Q4 24
5.7%
Q3 24
8.7%
Q2 24
6.9%
EPS (diluted)
CLB
CLB
LQDA
LQDA
Q1 26
$0.11
Q4 25
$0.11
$0.18
Q3 25
$0.30
$-0.04
Q2 25
$0.22
Q1 25
$0.00
Q4 24
$0.15
Q3 24
$0.25
Q2 24
$0.19

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CLB
CLB
LQDA
LQDA
Cash + ST InvestmentsLiquidity on hand
$22.8M
$190.7M
Total DebtLower is stronger
Stockholders' EquityBook value
$275.1M
$44.7M
Total Assets
$587.7M
$327.9M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CLB
CLB
LQDA
LQDA
Q1 26
$22.8M
Q4 25
$22.7M
$190.7M
Q3 25
$25.6M
$157.5M
Q2 25
$31.2M
Q1 25
$22.1M
Q4 24
$19.2M
Q3 24
$21.5M
Q2 24
$17.7M
Total Debt
CLB
CLB
LQDA
LQDA
Q1 26
Q4 25
$110.3M
Q3 25
$114.1M
Q2 25
$124.6M
Q1 25
$124.4M
Q4 24
$126.1M
Q3 24
$139.9M
Q2 24
$147.6M
Stockholders' Equity
CLB
CLB
LQDA
LQDA
Q1 26
$275.1M
Q4 25
$266.0M
$44.7M
Q3 25
$271.3M
$22.1M
Q2 25
$261.3M
Q1 25
$253.4M
Q4 24
$246.6M
Q3 24
$250.7M
Q2 24
$240.3M
Total Assets
CLB
CLB
LQDA
LQDA
Q1 26
$587.7M
Q4 25
$584.0M
$327.9M
Q3 25
$591.4M
$276.0M
Q2 25
$602.1M
Q1 25
$591.5M
Q4 24
$585.1M
Q3 24
$600.5M
Q2 24
$597.8M
Debt / Equity
CLB
CLB
LQDA
LQDA
Q1 26
Q4 25
0.41×
Q3 25
0.42×
Q2 25
0.48×
Q1 25
0.49×
Q4 24
0.51×
Q3 24
0.56×
Q2 24
0.61×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CLB
CLB
LQDA
LQDA
Operating Cash FlowLast quarter
$4.0M
$44.2M
Free Cash FlowOCF − Capex
$517.0K
$42.2M
FCF MarginFCF / Revenue
0.4%
45.9%
Capex IntensityCapex / Revenue
2.2%
Cash ConversionOCF / Net Profit
0.77×
3.04×
TTM Free Cash FlowTrailing 4 quarters
$22.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CLB
CLB
LQDA
LQDA
Q1 26
$4.0M
Q4 25
$7.9M
$44.2M
Q3 25
$8.5M
$-9.8M
Q2 25
$13.9M
Q1 25
$6.7M
Q4 24
$20.6M
Q3 24
$13.1M
Q2 24
$17.1M
Free Cash Flow
CLB
CLB
LQDA
LQDA
Q1 26
$517.0K
Q4 25
$5.0M
$42.2M
Q3 25
$6.5M
$-10.7M
Q2 25
$10.4M
Q1 25
$3.9M
Q4 24
$17.4M
Q3 24
$10.4M
Q2 24
$14.3M
FCF Margin
CLB
CLB
LQDA
LQDA
Q1 26
0.4%
Q4 25
3.6%
45.9%
Q3 25
4.8%
-19.7%
Q2 25
8.0%
Q1 25
3.1%
Q4 24
13.4%
Q3 24
7.7%
Q2 24
10.9%
Capex Intensity
CLB
CLB
LQDA
LQDA
Q1 26
Q4 25
2.1%
2.2%
Q3 25
1.5%
1.7%
Q2 25
2.7%
Q1 25
2.3%
Q4 24
2.5%
Q3 24
2.0%
Q2 24
2.2%
Cash Conversion
CLB
CLB
LQDA
LQDA
Q1 26
0.77×
Q4 25
1.61×
3.04×
Q3 25
0.60×
Q2 25
1.31×
Q1 25
Q4 24
2.78×
Q3 24
1.12×
Q2 24
1.90×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons